In vitro antimyeloma activity of the iron chelator deferasirox (DFX).

被引：0
|
作者：
Willenbacher, Ella [1 ]
Willenbacher, Wolfgang [1 ]
Funk, Ulrike [1 ]
Kircher, Brigitte [1 ]
机构：
[1] Med Univ Innsbruck, A-6020 Innsbruck, Austria
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19587
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Failure of deferasirox, an iron chelator agent, combined with antifungals in a case of severe zygomycosis
    Soummer, Alexis
    Mathonnet, Armelle
    Scatton, Olivier
    Massault, Pierre Philippe
    Paugam, Andre
    Lemiale, Virginie
    Mira, Jean Paul
    Dannaoui, Eric
    Cariou, Alain
    Lortholary, Olivier
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (04) : 1585 - 1586
  • [32] Immunological Evialuation of β-Thalassemia Major Patients Receiving Oral Iron Chelator Deferasirox
    Aleem, Aamer
    Shakoor, Zahid
    Alsaleh, Khalid
    Algahtani, Farjah
    Iqbal, Zafar
    Al-Momen, Abdulkareem
    JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2014, 24 (07): : 467 - 471
  • [33] Long-term effects of an oral iron chelator, deferasirox, in hemodialysis patients with iron overload
    Chen, Cheng-Hsu
    Shu, Kuo-Hsiung
    Yang, Youngsen
    HEMATOLOGY, 2015, 20 (05) : 304 - 310
  • [34] Restoration of cardiac function by an iron chelator, deferasirox, in a patient with aplastic anemia and cardiac iron overload
    Kiguchi, Toru
    Ito, Yoshikazu
    Kimura, Yukihiko
    Ohyashiki, Kazuma
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2009, 89 (04) : 546 - 548
  • [35] Restoration of cardiac function by an iron chelator, deferasirox, in a patient with aplastic anemia and cardiac iron overload
    Toru Kiguchi
    Yoshikazu Ito
    Yukihiko Kimura
    Kazuma Ohyashiki
    International Journal of Hematology, 2009, 89 : 546 - 548
  • [36] Using the Iron Chelator Deferasirox to Overcome Venetoclax Resistance in Mantle Cell Lymphoma
    Halperin, Erez
    Shapira, Saar
    Samara, Ala Aladin
    Raanani, Pia
    Granot, Galit
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S514 - S514
  • [37] Using the Iron Chelator Deferasirox to Overcome Drug Resistance in Mantle Cell Lymphoma
    Samara, Aladin
    Shapira, Saar
    Lubin, Ido
    Raanani, Pia
    Granot, Galit
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S408 - S409
  • [38] Deferasirox, a trivalent iron chelator, ameliorates neuronal damage in hemorrhagic stroke models
    Takahiko Imai
    Shohei Tsuji
    Hirohumi Matsubara
    Takuya Ohba
    Tomoki Sugiyama
    Shinsuke Nakamura
    Hideaki Hara
    Masamitsu Shimazawa
    Naunyn-Schmiedeberg's Archives of Pharmacology, 2021, 394 : 73 - 84
  • [39] Using the Iron Chelator Deferasirox to Overcome Drug Resistance in Mantle Cell Lymphoma
    Samara, Aladin
    Shapira, Saar
    Lubin, Ido
    Raanani, Pia
    Granot, Galit
    BLOOD, 2021, 138
  • [40] The effect of the iron chelator Deferasirox in combination with Cisplatin chemotherapy against lung carcinoma
    Torres, Priscilla M. Rodriguez
    Perez, Daraishka
    Ferrer, Yancy
    Delgado, Yamixa
    FASEB JOURNAL, 2022, 36
12345